D-0677-2026 Class II Ongoing

Recalled by Padagis US LLC — Minneapolis, MN

FDA drug recall D-0677-2026 was initiated by Padagis US LLC on Jun 23, 2026 and is designated Class II. Reason for recall: Subpotent Drug: Low out of specification assay results performed during long-term stability testing. The recall status is ongoing. Affected quantity: 180,936 tubes.

Recall details

Product Type
Drugs
Report Date
Jul 22, 2026
Initiation Date
Jun 23, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
180,936 tubes

Product description

Nystatin Cream USP, (100,000 USP Nystatin Units), NET WT 15 g, Rx only, 15 g tube, Manufactured by Padagis, Yeruham, Israel, NDC 45802-059-35

Reason for recall

Subpotent Drug: Low out of specification assay results performed during long-term stability testing.

Distribution pattern

USA Nationwide

Code information

Lot #: 205060, Exp 09/30/2027

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0677-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0677-2026. Report a data issue: hello@regdatalab.com.